Foundayo 17.2 mg shows greater weight loss and A1C reductions vs oral semaglutide (indirect study)
Sep 29, 2026, 3:27 AM EDT8 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Indirect efficacy advantages for Foundayo could shift investor perception of Lilly's pipeline momentum and potential future market share gains against Novo's oral GLP-1, especially if validated by direct data or regulatory progression; historically, new efficacy signals in GLP-1 space have prompted modest near-term equity moves.
AI summary
What happened, with direct paths to the underlying reporting
Eli Lilly reports an indirect analysis indicating Foundayo 17.2 mg achieves greater weight loss and A1C reduction versus oral semaglutide 25 mg at 52 weeks, based on ACHIEVE-3 and PIONEER PLUS data presented at EASD. While not head-to-head, the findings bolster Foundayo's competitive position in GLP-1 therapies and may support broader adoption in obesity and type 2 diabetes contexts.
Foundayo 17.2 mg shows 1.5% more weight loss vs oral semaglutide 25 mg.
A1C reduction is 0.3% greater at 52 weeks in indirect comparison.
ACHIEVE-3 data: 9 mg/17.2 mg outperform oral semaglutide in A1C and weight.
Data drawn from ACHIEVE-3 and PIONEER PLUS, presented at EASD.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
New post-hoc analyses from Lilly's LUCENT and VIVID programs show Omvoh delivering multidimensional disease control in ulcerative colitis and corticosteroid-free deep remission in…
The article notes healthcare was one of the few bright spots in Wednesday's trading and provides no LLY-specific data or catalysts. While speculative, sector breadth could lift la…
Gate Bioscience expanded its research and licensing agreement with Eli Lilly to develop treatments targeting disease-causing proteins, potentially worth more than $870 million. Th…
Amylin-targeting eloralintide, paired with tirzepatide, produced notable Phase 2 weight-loss results, including 23.3% loss at 48 weeks in the high-dose combo. Standalone and combi…
